Ulcerative colitis - treatment with biologicals

Teixeira, Fabio Vieira; Vilela, Eduardo Garcia; Damião, Aderson Omar Mourão Cintra; Vieira, Andrea; Albuquerque, Idblan Carvalho De; Parente, José Miguel Luz; Chebli, Júlio Maria Fonseca; Ambrogini Junior, Orlando; Hossne, Rogerio Saad; Miszputen, Sender Jankiel.
Rev. Assoc. Med. Bras. (1992) ; 65(4): 547-553, Apr. 2019.
Artículo en Inglés | LILACS | ID: biblio-1003058

Documentos relacionados

  1. Ulcerative colitis - treatment with biologicals.
  2. Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study.
  3. Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing.
  4. Treatment of Ulcerative Colitis: Impact on Platelet Aggregation.
  5. Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.
  6. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
  7. Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).
  8. Efficacy of tofacitinib treatment in ulcerative colitis.
  9. MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases.
  10. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.